ClinicalTrials.gg
TerminatedNCT03779113Updated Feb 18, 2026Results posted

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

A Phase 1 interventional study of HMPL-523 in Non Hodgkin Lymphoma, sponsored by Hutchmed. Terminated at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated by sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Lymphoma, Non-Hodgkin with a site in Spain — 21 open to participants now, 51 under way, 13 of them phase 3. Lymphoma, Non-Hodgkin · Spain.

Enrollment
109th of 156
69 · median 138
Started
2019
with 17 others
Phase 1
48 of 158
8 open now
Registered
85th of 158
by date

Among the 158 studies in Lymphoma, Non-Hodgkin with a site in Spain, this one is the 109th largest by enrollment of the 156 interventional ones that give a count, is one of 18 that started in 2019, is one of 48 in phase 1, and was the 85th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

21 of the 158 studies in Lymphoma, Non-Hodgkin with a site in Spain are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Lymphoma, Non-Hodgkin with a site in Spain, or all of them as a file.
02

Study summary

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

Read the detailed description

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

Dose Escalation Stage (Stage 1)

Dosing will begin at 100 mg once daily (QD). A cycle of study treatment will be defined as 28 days of continuous dosing. The modified 3+3 design will be applied for dose escalation and MTD determination to limit the number of patients exposed to potentially ineffective or unsafe doses. The study will enroll 1 patient and the patient will be treated for a 28-day cycle in the initial dose cohort. If there is no Dose Limiting Toxicity (DLT) and no more than 2 treatment-emergent adverse events (TEAEs) of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 in the first treatment cycle, the study will be escalated to the next dose cohort and continue with the standard 3+3 design. Otherwise, the trial will revert to a standard 3+3 design from the initial dose cohort. A minimum of 3 patients will be enrolled and observed for toxicity in each successive dose cohort after the initial dose cohort. If the 3 patients initially enrolled in a given dose cohort complete the DLT assessment window (Cycle 1, Days 1-28) without experiencing a DLT, 3 patients will be enrolled at the next higher dose level. If 2 or more of the initial 3 patients enrolled at any dose level experience a DLT during the DLT assessment window, the dose escalation will be halted. If 1 of the initial 3 patients enrolled at any dose level experiences a DLT during the DLT assessment window, additional patients will be enrolled at that dose level for a minimum of 6 evaluable patients for DLT. If a DLT is observed in 1 of the 6 valuable patients at this dose level, dose escalation will proceed to the next pre- defined dose level. If DLTs are observed in 2 or more of the 6 evaluable patients at a given dose level, the dose escalation will be halted. If the dose escalation is completed due to 2 or more DLTs at a dose level and that dose level is ≥50% higher than the previous dose level, then an intermediate dose level may be evaluated for toxicity in the same manner as described above. If the dose level is \<50% higher than the previous dose level, in which only 3 DLT evaluable patients were enrolled, 3 additional patients will be enrolled at that dose level to comprise 6 DLT evaluable patients.

The proposed dose escalation scheme comprises Cohorts 1 to 5 with dosing levels of 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD and 800 mg QD, respectively. The need for dose escalation beyond 800 mg QD, the specific dose to be tested and the potential for twice-daily (BID) dosing will be evaluated jointly by investigators and the sponsor based on the cumulative clinical safety, pharmacokinetic, and preliminary efficacy data. Safety monitoring and evaluation of dose escalation will be carried out by the Safety Review Committee, which will be comprised of the sponsor's study team members (including medical monitor, safety monitor and and Pharmacokinetic scientist) and the site principal investigators. The adverse event profile and serum concentration of HMPL-523 data will be evaluated to determine whether it is safe to continue the assigned HMPL-523 dose for dose escalation or whether the dose should be de-escalated to the lower dose level.

Dose Expansion Stage (Stage 2)

The adverse event profile, serum concentration, and preliminary anti-tumor activity of HMPL-523 at the maximum tolerated dose(MTD)/recommended phase 2 dose(RP2D) will be further evaluated in approximately 50 patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphomas. The tumor types of the dose expansion stage are restricted to:

  • 10 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
  • 20 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post-BTK exposure
  • 10 patients with mantle cell lymphoma
  • 20 patients with follicular lymphoma (Grade 1-3a)
  • 10 patients with marginal zone lymphoma
  • 10 patients with waldenström's macroglobulinemia/lymphoplasmacytic lymphoma
  • 10 patients with peripheral T- cell lymphoma
  • 10 patients with cutaneous B-cell lymphoma
  • 10 patients with hodgkin lymphoma

Patients will receive HMPL-523 at the MTD/RP2D for continuous 28-day treatment cycles until disease progression, death, intolerable toxicity, at investigator's discretion that the patient can no longer benefit from the study treatment, patient withdrawal from the study, or the end of study, whichever comes first.

03

Conditions studied

  • Non Hodgkin Lymphoma

Keywords

  • lymphoma
  • chronic lymphocytic leukemia
  • Hodgkin lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet the following criteria to be eligible for study entry:

  1. Signed form (ICF).
  2. Age ≥18 years.
  3. performance status of 0 or 1.
  4. confirmed lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. In the dose expansion stage, the tumor types may be restricted to any or all of the following tumor types. There may be approximately 10 patients in each cohort depending on response signals suggesting efficacy, except for 2 identified cohorts with approximately 20 patients per cohort: CLL/SLL, CLL/SLL post-BTK exposure (n=20), MCL, FL (Grade 1-3a) (n=20), MZL, WM/LPL, PTCL,CBCL, and/or HL
  5. Patients with relapsed or refractory lymphoma who have exhausted all approved therapy options.
  6. In the dose expansion stage, patients must have for an objective response assessment, except for patients with CLL and WM/LPL
  7. Availability of tumor sample for patients in dose expansion cohorts: This may be an sample obtained after most recent therapy or a fresh biopsy; if tumor sample is not available, the Sponsor may waive the requirement after discussion
  8. Expected survival of more than 24 weeks as determined by the investigator.
  9. Male patients must agree to use a condom and female patients of must agree to use highly effective measures for 30 days after the last dose of study drug. These include as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, and transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, and implantable), intrauterine contraceptive device, intrauterine hormone release system, bilateral tubal occlusion, or a vasectomized partner, provided that male partner is the sole sexual partner of the female patient. females (women who have not had menses for at least 1 year without an alternative medical cause) are exempt from this criterion.

Exclusion criteria

Exclusion Criteria

  1. Patients with primary central nervous system (CNS) lymphoma.
  2. Any of the following laboratory abnormalities: \<1.0×10\^9/L, \<80 g/L, \<50×10\^9/L
  3. Inadequate organ function, defined by the following: Total >1.5 times the (× ULN), and/or alanine aminotransferase >2.5 × ULN, Estimated (CrCl) per Cockcroft-Gault [Dose Escalation portion of trial (Stage 1) CrCl \< 40 mL/min, Dose Expansion portion of trial (Stage 2) CrCl \< 30 mL/min], Serum amylase or lipase >ULN, >1.5 × ULN, or activated partial thromboplastin time >1.5 × ULN
  4. Patients with clinically detectable second primary malignant tumors at enrollment or other malignant tumors within the last 2 years (with the exception of radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix, or in situ breast cancer).
  5. Any anticancer therapy, including chemotherapy, hormonal therapy, biologic therapy, vaccine, or radiotherapy within 3 weeks prior to the initiation of study treatment.
  6. Herbal therapy within 1 week prior to the initiation of study treatment.
  7. Prior use of any anti-cancer vaccine
  8. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)
  9. Prior administration of radioimmunotherapy within 3 months before initiation of study treatment.
  10. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450 isoform 1A2, and are identified as narrow therapeutic drugs within 7 days or 3 half-lives, whichever is longer, prior to initiation of study treatment
  11. Adverse events from prior anticancer therapy that have not resolved to Grade ≤1, except for alopecia.
  12. Prior stem cell transplant within 6 months prior to the initiation of study treatment.
  13. Prior allogeneic stem cell transplant within 6 months prior to the initiation of study treatment or with any evidence of active or requirement for within 28 days prior to the initiation of study treatment.
  14. active infection (eg, pneumonia).
  15. Major surgical procedure within 4 weeks prior to the initiation of study treatment.
  16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with , virus, or virus.
  17. Pregnant (positive serum beta human chorionic gonadotropin test) or lactating women.
  18. Class II or greater congestive heart failure.
  19. Congenital long syndrome or correct QT interval using Fridericia's formula (QTcF) >480 msec
  20. Current use of medication known to cause QT prolongation or Torsades de Pointes
  21. History of myocardial infarction or unstable angina within 6 months prior to the initiation of study treatment.
  22. History of stroke or within 6 months prior to the initiation of study treatment.
  23. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease.
  24. Treatment in a clinical study within 30 days prior to the initiation of study treatment.
  25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an drug, may affect the interpretation of the results, or renders the patient at high risk from treatment complications.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Treatment

    All patients to received study drug (HMPL-523)

    Drug: HMPL-523

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)

    A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study treatment. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of Grade 3 or greater with the exception of Grade 3 nausea or vomiting controlled by supportive therapy; hematologic toxicity: Grade 4 neutropenia \>5 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or which required platelets transfusion, Grade \>=3 febrile neutropenia (defined as absolute neutrophil count \<1000/cubic millimeter with a single temperature \>38.3 degree Celsius \[°C\] or a sustained temperature of \>=38°C for more than 1 hour), Grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of \>=15 days; any case of Hy's Law.

    Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)

  2. Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation

    An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.

    Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months

  3. Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523

    RP2D was based on the pharmacokinetics (PK), safety, and tolerability assessments in dose escalation stage patients.

    Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)

  4. Dose Expansion Stage: Objective Response Rate (ORR)

    ORR:percentage of patients who had best overall response (BOR) with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR) or PR for CLL patients; CR, very good PR(VGPR), PR or minor response(MR) for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR:best response from start of treatment until progression or any further anticancer therapy.CR:absence of serum(S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR:patients with residual CLL cells. PR, VGPR, MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR:\>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  5. Dose Expansion Stage: Complete Response Rate

    CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  6. Dose Expansion Stage: Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of patients who had BOR of stable disease (SD) or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  7. Dose Expansion Stage: Duration of Response (DOR)

    DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR,MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM,complete resolution of extramedullary disease,MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  8. Dose Expansion Stage: Time to Response (TTR)

    TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in serum IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in serum IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in serum IgM. Kaplan Meier analysis included only the responders.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  9. Dose Expansion Stage: Progression-Free Survival (PFS)

    PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

Secondary outcomes

  1. Dose Escalation Stage and Dose Expansion Stage: Maximum Plasma Concentration (Cmax) of HMPL-523

    Blood samples were collected to determine Cmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1

  2. Dose Escalation Stage and Dose Expansion Stage: Time to Reach Maximum Plasma Concentration (Tmax) of HMPL-523

    Blood samples were collected to determine tmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1

  3. Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523

    Blood samples were collected to determine AUC0-t of HMPL-523. The PK parameters were determined by non-compartmental analysis.

    Time frame: Dose escalation and dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 1 of Cycle 1

  4. Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of HMPL-523

    Blood samples were collected to determine AUCtau of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1

  5. Dose Escalation Stage and Dose Expansion Stage: Apparent Systemic Clearance (CL/F) of HMPL-523

    Blood samples were collected to determine CL/F of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  6. Dose Escalation Stage and Dose Expansion Stage: Minimum Plasma Concentration (Cmin) of HMPL-523

    Blood samples were collected to determine Cmin of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  7. Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Maximum Plasma Concentration (MRCmax)

    Blood samples were collected to determine MRCmax. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  8. Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Area Under the Concentration-Time Curve During a Dosing Interval (MRAUCtau)

    Blood samples were collected to determine MRAUCtau. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  9. Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Maximum Plasma Concentration (RA[Cmax]) of HMPL-523

    Blood samples were collected to determine RA(Cmax) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  10. Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Area Under the Concentration-Time Curve During a Dosing Interval (RA[AUC]) of HMPL-523

    Blood samples were collected to determine RA(AUC) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

    Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1

  11. Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation

    An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.

    Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months

  12. Dose Escalation Stage: Objective Response Rate

    ORR: percentage of patients who had BOR with CR, CRi, nPR or PR for CLL patients; CR, VGPR, PR or MR for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR: best response from start of treatment until progression or any further anticancer therapy. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  13. Dose Escalation Stage: Complete Response Rate

    CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  14. Dose Escalation Stage: Clinical Benefit Rate

    CBR was defined as the percentage of patients who had BOR of SD or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  15. Dose Escalation Stage: Duration of Response

    DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  16. Dose Escalation Stage: Time to Response

    TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. Kaplan Meier analysis included only the responders.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

  17. Dose Escalation Stage: Progression-Free Survival

    PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

07

Results

Posted Feb 18, 2026
Limitations and caveats
The study was terminated based on strategic decision made by the Sponsor to discontinue development of HMPL-523 for lymphoma in the United States, Europe, and Australia with no safety concerns.

Participant flow

This Phase 1 open-label study was conducted in patients with relapsed or refractory lymphoma who had exhausted approved therapy options. Study recruitment was terminated based on a strategic decision made by the Sponsor to discontinue development of HMPL-523 for lymphoma in the United States, Europe, and Australia with no safety concerns.

Participant flow — Overall Study
MilestoneDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Started433344251721129
Completed00000000000000
Not completed433344251721129
Withdrew: Adverse event00100100000000
Withdrew: Progressive disease322121130201004
Withdrew: Death00000120100013
Withdrew: Physician decision10000120000001
Withdrew: Withdrawal by subject01010051310110
Withdrew: Anti-neoplasm treatment00012010110001
Withdrew: Lost to follow-up00000010000000
Withdrew: Study terminated by sponsor00000010000000

Outcome measures

PrimaryDose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)

A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study treatment. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of Grade 3 or greater with the exception of Grade 3 nausea or vomiting controlled by supportive therapy; hematologic toxicity: Grade 4 neutropenia \>5 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or which required platelets transfusion, Grade \>=3 febrile neutropenia (defined as absolute neutrophil count \<1000/cubic millimeter with a single temperature \>38.3 degree Celsius \[°C\] or a sustained temperature of \>=38°C for more than 1 hour), Grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of \>=15 days; any case of Hy's Law.

Time frame:
From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
Reported as:
Count of participants · Participants
Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)
ParticipantsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)100002
PrimaryDose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.

Time frame:
From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
Reported as:
Count of participants · Participants
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation
ParticipantsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Any TEAE433344
Any Treatment related TEAE333333
Any TEAE leading to treatment interruption121222
Any TEAE leading to treatment reduction000003
Any TEAE leading to treatment discontinuation000012
PrimaryDose Escalation Stage: Recommended Phase 2 Dose of HMPL-523

RP2D was based on the pharmacokinetics (PK), safety, and tolerability assessments in dose escalation stage patients.

Time frame:
From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
Reported as:
Number · mg
Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523
mgDose Escalation Stage: HMPL-523
Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523700
PrimaryDose Expansion Stage: Objective Response Rate (ORR)

ORR:percentage of patients who had best overall response (BOR) with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR) or PR for CLL patients; CR, very good PR(VGPR), PR or minor response(MR) for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR:best response from start of treatment until progression or any further anticancer therapy.CR:absence of serum(S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR:patients with residual CLL cells. PR, VGPR, MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR:\>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Expansion Stage: Objective Response Rate (ORR)
percentage of patientsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Objective Response Rate (ORR)24.0 (9.4 to 45.1)100 (2.5 to 100.0)28.6 (3.7 to 71.0)0 (0.0 to 84.2)0 (0.0 to 97.5)100 (2.5 to 100.0)0 (0.0 to 97.5)37.5 (8.5 to 75.5)
PrimaryDose Expansion Stage: Complete Response Rate

CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Expansion Stage: Complete Response Rate
percentage of patientsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Complete Response Rate8.0 (1.0 to 26.0)100 (2.5 to 100.0)0 (0.0 to 41.0)0 (0.0 to 84.2)0 (0.0 to 97.5)0 (0.0 to 97.5)0 (0.0 to 97.5)25.0 (3.2 to 65.1)
PrimaryDose Expansion Stage: Clinical Benefit Rate (CBR)

CBR was defined as the percentage of patients who had BOR of stable disease (SD) or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Expansion Stage: Clinical Benefit Rate (CBR)
percentage of patientsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Clinical Benefit Rate (CBR)64.0 (42.5 to 82.0)100 (2.5 to 100.0)71.4 (29.0 to 96.3)100 (15.8 to 100.0)100 (2.5 to 100.0)100 (2.5 to 100.0)0 (0.0 to 97.5)37.5 (8.5 to 75.5)
PrimaryDose Expansion Stage: Duration of Response (DOR)

DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR,MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM,complete resolution of extramedullary disease,MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Expansion Stage: Duration of Response (DOR)
monthsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Duration of Response (DOR)6.7 (1.9 to NA)NA (NA to NA)11.3 (10.6 to NA)——NA (NA to NA)—5.7 (2.0 to NA)
PrimaryDose Expansion Stage: Time to Response (TTR)

TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in serum IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in serum IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in serum IgM. Kaplan Meier analysis included only the responders.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Expansion Stage: Time to Response (TTR)
monthsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Time to Response (TTR)1.9 (1.4 to NA)24.8 (NA to NA)1.8 (1.7 to NA)——6.1 (NA to NA)—1.8 (1.4 to NA)
PrimaryDose Expansion Stage: Progression-Free Survival (PFS)

PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Expansion Stage: Progression-Free Survival (PFS)
monthsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Expansion Stage: Progression-Free Survival (PFS)3.6 (1.7 to 4.8)NA (NA to NA)12.3 (1.7 to NA)NA (NA to NA)5.1 (NA to NA)NA (NA to NA)1.4 (NA to NA)1.8 (0.8 to 7.2)
SecondaryDose Escalation Stage and Dose Expansion Stage: Maximum Plasma Concentration (Cmax) of HMPL-523

Blood samples were collected to determine Cmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Reported as:
Mean · nanograms per milliliter (ng/mL)
Dose Escalation Stage and Dose Expansion Stage: Maximum Plasma Concentration (Cmax) of HMPL-523
nanograms per milliliter (ng/mL)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 136.43 ± 33.9851.93 ± 10.4558.00 ± 19.24109.3 ± 11.55126.3 ± 45.55208.5 ± 115.9173.1 ± 106.5131.8 ± 61.33NA ± NANA ± NANA ± NANA ± NA150.0 ± 71.30
Cycle 1 Day 1532.53 ± 14.0052.27 ± 10.90118.1 ± 49.25233.7 ± 42.83218.0 ± 37.16NA ± NA———————
Cycle 1 Day 2836.10 ± 13.0852.70 ± 12.30104.7 ± 19.55169.3 ± 67.28249.7 ± 59.72NA ± NA229.0 ± 113.7195.5 ± 153.6NA ± NA—NA ± NANA ± NA240.7 ± 84.51
SecondaryDose Escalation Stage and Dose Expansion Stage: Time to Reach Maximum Plasma Concentration (Tmax) of HMPL-523

Blood samples were collected to determine tmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Reported as:
Median · hour (h)
Dose Escalation Stage and Dose Expansion Stage: Time to Reach Maximum Plasma Concentration (Tmax) of HMPL-523
hour (h)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 15.84 (2.00 to 6.00)5.92 (4.00 to 5.98)5.80 (4.02 to 7.75)3.83 (1.07 to 7.75)4.09 (4.00 to 6.00)6.02 (1.00 to 6.05)4.00 (1.00 to 6.03)2.17 (1.00 to 6.00)NA (1.98 to 4.17)NA (23.50 to 23.50)NA (4.00 to 4.00)NA (4.00 to 4.00)4.00 (2.00 to 7.52)
Cycle 1 Day 155.00 (2.00 to 7.83)4.98 (2.00 to 6.00)3.90 (2.02 to 5.92)3.98 (1.95 to 4.00)4.22 (4.08 to 5.83)NA (6.00 to 6.00)———————
Cycle 1 Day 285.92 (4.00 to 8.00)6.00 (4.08 to 6.02)4.00 (2.00 to 6.12)4.20 (2.02 to 6.00)5.78 (3.98 to 5.98)NA (1.83 to 1.83)4.03 (2.00 to 7.97)4.93 (2.08 to 24.17)NA (6.17 to 6.17)—NA (8.00 to 8.00)NA (2.00 to 2.00)4.10 (4.00 to 25.33)
SecondaryDose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523

Blood samples were collected to determine AUC0-t of HMPL-523. The PK parameters were determined by non-compartmental analysis.

Time frame:
Dose escalation and dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · ng*h/mL
Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523
ng*h/mLDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523352.3 ± 247.5589.1 ± 77.22734.1 ± 195.01278 ± 50.631608 ± 469.12624 ± 12441771 ± 864.51568 ± 676.6NA ± NANA ± NANA ± NANA ± NA1622 ± 686.5
SecondaryDose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of HMPL-523

Blood samples were collected to determine AUCtau of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Reported as:
Mean · ng*h/mL
Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of HMPL-523
ng*h/mLDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 1352.3 ± 247.5589.1 ± 77.22NA ± NA1278 ± 50.631608 ± 469.12624 ± 12441759 ± 886.31568 ± 43.1NA ± NANA ± NANA ± NANA ± NA1622 ± 686.5
Cycle 1 Day 15457.4 ± 184.9NA ± NA1346 ± 382.82618 ± 864.33291 ± 679.7NA ± NA———————
Cycle 1 Day 28562.5 ± 193.4765.1 ± 150.91298 ± 341.2NA ± NA3832 ± 1080—3324 ± 17352848 ± 1929NA ± NA—NA ± NANA ± NA3621 ± 1273
SecondaryDose Escalation Stage and Dose Expansion Stage: Apparent Systemic Clearance (CL/F) of HMPL-523

Blood samples were collected to determine CL/F of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · Liter/h
Dose Escalation Stage and Dose Expansion Stage: Apparent Systemic Clearance (CL/F) of HMPL-523
Liter/hDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 15249.3 ± 101.3NA ± NA313.3 ± 85.63247.8 ± 86.15219.8 ± 51.17NA ± NA———————
Cycle 1 Day 28190.8 ± 56.92269.2 ± 59.18321.2 ± 74.49NA ± NA194.9 ± 65.24—275.0 ± 142.3360.9 ± 220.8NA ± NA—NA ± NANA ± NA213.1 ± 71.20
SecondaryDose Escalation Stage and Dose Expansion Stage: Minimum Plasma Concentration (Cmin) of HMPL-523

Blood samples were collected to determine Cmin of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · ng/mL
Dose Escalation Stage and Dose Expansion Stage: Minimum Plasma Concentration (Cmin) of HMPL-523
ng/mLDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 1511.07 ± 6.63910.64 ± 3.68826.17 ± 11.3539.44 ± 39.4860.90 ± 18.07NA ± NA———————
Cycle 1 Day 2810.51 ± 2.32712.23 ± 1.10230.10 ± 17.3040.10 ± 27.9265.80 ± 24.68—66.09 ± 45.0460.40 ± 42.23NA ± NA—NA ± NANA ± NA62.23 ± 22.62
SecondaryDose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Maximum Plasma Concentration (MRCmax)

Blood samples were collected to determine MRCmax. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · ratio
Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Maximum Plasma Concentration (MRCmax)
ratioDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
M1: Cycle 1 Day 150.5991 ± 0.29330.7537 ± 0.45870.7159 ± 0.37630.5895 ± 0.12360.8991 ± 0.3522NA ± NA———————
M1: Cycle 1 Day 280.4787 ± 0.26750.5856 ± 0.10120.7050 ± 0.44320.6903 ± 0.046380.8849 ± 0.3142NA ± NA0.7690 ± 0.30100.6421 ± 0.2987NA ± NA—NA ± NANA ± NA0.5671 ± 0.3079
M44: Cycle 1 Day 150.8269 ± 0.61840.5329 ± 0.33030.3375 ± 0.25510.2984 ± 0.080070.1643 ± 0.02048NA ± NA———————
M44: Cycle 1 Day 281.348 ± 1.0660.6394 ± 0.43930.2326 ± 0.12650.3579 ± 0.12910.1981 ± 0.08459NA ± NA0.3582 ± 0.32260.5167 ± 0.4552NA ± NA—NA ± NANA ± NA0.6787 ± 0.8715
SecondaryDose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Area Under the Concentration-Time Curve During a Dosing Interval (MRAUCtau)

Blood samples were collected to determine MRAUCtau. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · ratio
Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Area Under the Concentration-Time Curve During a Dosing Interval (MRAUCtau)
ratioDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
M1: Cycle 1 Day 150.6036 ± 0.2634NA ± NA0.6525 ± 0.34390.5678 ± 0.089230.7382 ± 0.2924NA ± NA———————
M1: Cycle 1 Day 280.5254 ± 0.29370.6092 ± 0.11960.6441 ± 0.3541NA ± NA0.7391 ± 0.2139—0.7104 ± 0.25890.5776 ± 0.2271NA ± NA—NA ± NANA ± NA0.5219 ± 0.2584
M44: Cycle 1 Day 150.3717 ± 0.2715NA ± NA0.1610 ± 0.11240.1691 ± 0.067300.08454 ± 0.03028NA ± NA———————
M44: Cycle 1 Day 280.5559 ± 0.57380.2030 ± 0.067310.1573 ± 0.1300NA ± NA0.09547 ± 0.03969—0.2145 ± 0.18070.2147 ± 0.1247NA ± NA—NA ± NANA ± NA0.2864 ± 0.2716
SecondaryDose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Maximum Plasma Concentration (RA[Cmax]) of HMPL-523

Blood samples were collected to determine RA(Cmax) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · ratio
Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Maximum Plasma Concentration (RA[Cmax]) of HMPL-523
ratioDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 151.187 ± 0.54081.020 ± 0.19922.126 ± 0.75672.151 ± 0.42411.468 ± 0.2829NA ± NA———————
Cycle 1 Day 281.579 ± 1.1481.065 ± 0.39911.982 ± 0.83501.558 ± 0.62341.683 ± 0.4367NA ± NA1.488 ± 0.54401.955 ± 0.4608NA ± NA—NA ± NANA ± NA1.917 ± 1.229
SecondaryDose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Area Under the Concentration-Time Curve During a Dosing Interval (RA[AUC]) of HMPL-523

Blood samples were collected to determine RA(AUC) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.

Time frame:
Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Reported as:
Mean · ratio
Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Area Under the Concentration-Time Curve During a Dosing Interval (RA[AUC]) of HMPL-523
ratioDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLL and CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Cycle 1 Day 151.590 ± 0.8423NA ± NANA ± NA2.049 ± 0.65941.805 ± 0.3995NA ± NA———————
Cycle 1 Day 282.358 ± 1.5451.305 ± 0.2577NA ± NANA ± NA2.102 ± 0.6167—1.855 ± 0.59612.324 ± 0.6424NA ± NA—NA ± NANA ± NA2.326 ± 0.8264
SecondaryDose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation

An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.

Time frame:
From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
Reported as:
Count of participants · Participants
Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation
ParticipantsDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
Any TEAE250721129
Any Treatment related TEAE190621027
Any TEAE leading to treatment interruption120610114
Any TEAE leading to treatment reduction00401010
Any TEAE leading to treatment discontinuation00111000
SecondaryDose Escalation Stage: Objective Response Rate

ORR: percentage of patients who had BOR with CR, CRi, nPR or PR for CLL patients; CR, VGPR, PR or MR for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR: best response from start of treatment until progression or any further anticancer therapy. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Escalation Stage: Objective Response Rate
percentage of patientsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Objective Response Rate0 (0.0 to 60.2)0 (0.0 to 70.8)50.0 (1.3 to 98.7)33.3 (0.8 to 90.6)33.3 (0.8 to 90.6)50.0 (6.8 to 93.2)
SecondaryDose Escalation Stage: Complete Response Rate

CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Escalation Stage: Complete Response Rate
percentage of patientsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Complete Response Rate0 (0.0 to 60.2)0 (0.0 to 70.8)0 (0.0 to 84.2)33.3 (0.8 to 90.6)0 (0.0 to 70.8)50.0 (6.8 to 93.2)
SecondaryDose Escalation Stage: Clinical Benefit Rate

CBR was defined as the percentage of patients who had BOR of SD or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Number · percentage of patients
Dose Escalation Stage: Clinical Benefit Rate
percentage of patientsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Clinical Benefit Rate0 (0.0 to 60.2)0 (0.0 to 70.8)100 (15.8 to 100.0)66.7 (9.4 to 99.2)33.3 (0.8 to 90.6)50.0 (6.8 to 93.2)
SecondaryDose Escalation Stage: Duration of Response

DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Escalation Stage: Duration of Response
monthsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Duration of Response——15.7 (NA to NA)25.9 (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryDose Escalation Stage: Time to Response

TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. Kaplan Meier analysis included only the responders.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Escalation Stage: Time to Response
monthsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Time to Response——6.7 (NA to NA)1.6 (NA to NA)1.6 (NA to NA)5.2 (1.1 to NA)
SecondaryDose Escalation Stage: Progression-Free Survival

PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Reported as:
Median · months
Dose Escalation Stage: Progression-Free Survival
monthsDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QD
Dose Escalation Stage: Progression-Free Survival1.3 (1.3 to NA)1.6 (1.0 to NA)12.9 (3.5 to NA)14.7 (1.9 to NA)1.9 (1.7 to NA)NA (0.9 to NA)

Adverse events

Collected over AEs and SAEs were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months for each stage (dose escalation and dose expansion). All-cause mortality (deaths) were collected from first dose of study treatment (Day 1) up to end of study visit, approximately 65 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Stage: HMPL-523 100 mg QD0/4 (0%)1/4 (25%)4/4 (100%)
Dose Escalation Stage: HMPL-523 200 mg QD0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation Stage: HMPL-523 400 mg QD0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Stage: HMPL-523 600 mg QD0/3 (0%)1/3 (33.3%)3/3 (100%)
Dose Escalation Stage: HMPL-523 700 mg QD0/4 (0%)0/4 (0%)4/4 (100%)
Dose Escalation Stage: HMPL-523 800 mg QD1/4 (25%)3/4 (75%)4/4 (100%)
Dose Expansion Stage: HL2/25 (8%)6/25 (24%)25/25 (100%)
Dose Expansion Stage: CLL0/1 (0%)0/1 (0%)0/1 (0%)
Dose Expansion Stage: CLL-post BTK1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Dose Expansion Stage: FL0/2 (0%)2/2 (100%)2/2 (100%)
Dose Expansion Stage: MZL0/1 (0%)0/1 (0%)1/1 (100%)
Dose Expansion Stage: LPL/WM0/1 (0%)1/1 (100%)1/1 (100%)
Dose Expansion Stage: MCL1/2 (50%)0/2 (0%)2/2 (100%)
Dose Expansion Stage: PTCL3/9 (33.3%)5/9 (55.6%)9/9 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
PneumoniaInfections and infestations1/40/30/30/30/40/41/250/10/71/20/11/10/20/9
Febrile neutropeniaBlood and lymphatic system disorders0/40/30/30/30/40/40/250/13/71/20/10/10/20/9
Intestinal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/31/30/40/40/250/10/70/20/10/10/20/9
Atrial tachycardiaCardiac disorders0/41/30/30/30/40/40/250/10/70/20/10/10/20/9
Small intestinal obstructionGastrointestinal disorders0/41/30/30/30/40/40/250/10/70/20/10/10/20/9
Abortion spontaneous completePregnancy, puerperium and perinatal conditions0/40/31/30/30/40/40/250/10/70/20/10/10/20/9
COVID-19Infections and infestations0/40/30/30/30/41/40/250/11/70/20/10/10/20/9
Enterocolitis infectiousInfections and infestations0/40/30/30/30/41/40/250/10/70/20/10/10/20/9
Respiratory tract infectionInfections and infestations0/40/30/30/30/41/40/250/10/70/20/10/10/20/9
SepsisInfections and infestations0/40/30/30/30/41/40/250/10/70/20/10/10/20/9
Most frequent other events
Showing 10 of 93
Most frequent other events
EventDose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCL
AstheniaGeneral disorders0/40/31/31/31/41/42/250/11/70/20/11/11/20/9
FatigueGeneral disorders1/41/30/30/30/40/44/250/11/70/21/10/10/20/9
Amylase increasedInvestigations0/40/30/30/30/42/44/250/11/70/21/10/10/20/9
AnaemiaBlood and lymphatic system disorders2/41/31/31/30/41/46/250/13/72/20/10/10/23/9
NauseaGastrointestinal disorders0/40/30/31/31/42/410/250/13/70/21/10/10/22/9
VomitingGastrointestinal disorders0/40/30/30/30/42/44/250/11/70/21/10/10/21/9
Upper respiratory tract infectionInfections and infestations0/40/30/30/31/41/41/250/10/70/20/11/11/20/9
Urinary tract infectionInfections and infestations0/40/30/30/30/40/41/250/11/70/21/10/11/20/9
PruritusSkin and subcutaneous tissue disorders0/40/30/30/31/40/42/250/10/70/21/10/10/21/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/40/30/30/30/40/41/250/11/70/21/10/10/21/9

Baseline characteristics

The Full Analysis Set (FAS) included all patients who received at least 1 dose of HMPL-523.

Age, Continuous
Age, Continuous(years)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCLTotal
Mean69.8 ± 11.1255.0 ± 7.0057.7 ± 30.0953.0 ± 21.0756.3 ± 21.7258.8 ± 16.2842.8 ± 17.8376.065.1 ± 7.7675.5 ± 2.1293.067.069.5 ± 7.7864.4 ± 14.5356.1 ± 19.00
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCLTotal
Female01111210121111427
Male42223215051001542
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCLTotal
White42324419162112859
Black or African American010100100000014
Asian000000100000001
American Indian or Alaska Native000000100000001
Multiple000000100000001
Other000000201000003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation Stage: HMPL-523 100 mg QDDose Escalation Stage: HMPL-523 200 mg QDDose Escalation Stage: HMPL-523 400 mg QDDose Escalation Stage: HMPL-523 600 mg QDDose Escalation Stage: HMPL-523 700 mg QDDose Escalation Stage: HMPL-523 800 mg QDDose Expansion Stage: HLDose Expansion Stage: CLLDose Expansion Stage: CLL-post BTKDose Expansion Stage: FLDose Expansion Stage: MZLDose Expansion Stage: LPL/WMDose Expansion Stage: MCLDose Expansion Stage: PTCLTotal
Hispanic or Latino2211011020000414
Not Hispanic or Latino21224322152112452
Not Reported000000100000012
Unknown000000100000001
08

Study locations

32 sites
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Innovative Clinical Research Institute
    Downey, California 90241, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Clinical Research Alliance
    New Hyde Park, New York 11042, United States
  • Leo Jenkins Cancer Center/ECU School of Medicine
    Greenville, North Carolina 27834, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Renovatio Clinical
    The Woodlands, Texas 77380, United States
  • Aarhus University Hospital
    Aarhus, Denmark
  • Helsingin yliopistollinen keskussairaala
    Helsinki, 00029, Finland
  • Tampereen yliopistollinen sairaala
    Tampere, 33520, Finland
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont-Ferrand, France
  • Hôpital Henri Mondor
    Créteil, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, France
  • CHU Poitiers - Hôpital la Milétrie
    Poitiers, France
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    Bergamo, Bergamo 24127, Italy
  • Ospedale San Raffaele
    Milan, Milano 20132, Italy
  • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
    Monza, Italy
  • KO-MED Centra Kliniczne
    Biała Podlaska, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego
    Wroclaw, 50566, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • ICO Badalona - Hospital Universitari Germans Trias i Pujol
    Barcelona, Spain
  • Institut Català d'Oncologia
    Barcelona, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Fundacion Jimenez Diaz
    Madrid, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, Spain
  • Hospital Universitario Quironsalud Madrid
    Madrid, Spain
  • MD Anderson Cancer Centre
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Feb 2025, 65 months.

Results were first posted in Feb 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 19, 2018
StartActual
Sep 26, 2019
Primary completionActual
Feb 26, 2025
CompletionActual
Feb 26, 2025
Results first posted
Feb 18, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03779113
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Sep 26, 2019
Primary completion
Feb 26, 2025
Completion
Feb 26, 2025
Results posted
Feb 18, 2026
Last update
Feb 18, 2026

Study contacts

Michael Shi, MD
study director · Hutchmed

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion